Ambry Genetics is both CAP-accredited and CLIA-approved. Ambry is able to conduct genetic testing on samples received from any state in the US. In addition, Ambry has special licensure from the states listed below.

Licensing & Regulatory Number Expiration Date
CAP Accredited 7154701 October 26, 2018
CLIA Approved 05D0981414 May 29, 2018
State of California CLF 00011694 April 28, 2018
State of Florida 800016789 January 28, 2018
State of Maryland 1052 June 30, 2019
State of New York PFI: 8160 June 30, 2018
State of Rhode Island LCO01115 December 30, 2018
State of Pennsylvania 027832A August 15, 2017
Notice of Privacy Practices
Federalwide Assurance for the Protection of Human Subjects FWA#: FWA00024430 July 26, 2021

Proficiency Testing

Ambry Genetics participates in Proficiency Testing provided by the College of American Pathologists (CAP) for all available tests and performs Alternative Proficiency Testing where CAP does not provide an offering. In support of our International clients, Ambry also participates in the United Kingdom National External Quality Assessment Services (UK NEQAS) Molecular Genetics quality assessment schemes. Ambry’s Proficiency Testing program is essential in order to ensure nationally and internationally agreed upon consensus and/or standards in clinical laboratory testing are met.

Search Results

Start your search...